OpenEvidence AI Review: Free Medical Search for Doctors
Doctors must keep up with a flood of new research. OpenEvidence is an AI tool built to answer clinical questions with sources, and it has grown into one of the most heavily used and highly valued applications in healthcare AI.
This review covers what it does, who can use it, real adoption and accuracy data, and where it is limited, updated for September 2026.
What Is OpenEvidence
OpenEvidence is an AI medical research assistant. It searches peer reviewed journals and clinical guidelines and answers with citations so users can check the original sources. CEO Daniel Nadler has said more than 40% of US physicians now use the platform every day, with 757,000 verified physicians registered across more than 10,000 hospitals and medical centers as of early 2026.
Key Features
- Quick and deep answer modes
- Inline citations to studies
- Clinical calculators
- Clinical trial matching
- Voice queries
- Partnerships with medical publishers including Wiley
How It Works
- A verified clinician signs in.
- They type or speak a question.
- The tool searches trusted sources.
- It writes an answer with citations.
- The clinician checks the sources and decides.
Pricing
One 2026 review reports that OpenEvidence is free for verified US healthcare professionals and is funded by advertising. It also reports that the free model could change and that access has been limited in some regions. Check the official site for current access.
How Fast OpenEvidence Has Grown
OpenEvidence’s valuation climbed fast through 2025 and into 2026: $1 billion after its February 2025 Series A led by Sequoia Capital, $3.5 billion after a $210 million round in July 2025, $6 billion after a further $200 million round in October 2025, and $12 billion after a $250 million Series D in January 2026 led by Thrive Capital and DST Global. Total funding raised across all rounds is roughly $700 million. The company relocated its headquarters from Cambridge, Massachusetts to Miami’s Wynwood-adjacent design district in 2025, alongside Nadler’s move into a Miami Beach penthouse.
Pros
- Fast for routine questions
- Widely used by physicians, with 40%+ of US doctors reportedly using it daily
- Backed by major medical publisher partnerships
Cons
- Weaker on rare or complex cases according to one review
- Cannot replace professional judgment
- Access limited by region and verification
- Free model may change
- Independent research has found the same omission-error weakness that affects other medical AI tools
What an Independent Study Found About Its Accuracy
A 2026 independent benchmark called NOHARM, built by researchers from Stanford, Harvard, and the ARISE network, ran 1,100 actual clinical cases through OpenEvidence alongside OpenAI’s GPT-5.6 Sol, Anthropic’s Claude Fable 5, and Doximity Ask, collecting roughly 13,000 physician annotations to score potential patient harm. The study found that 76.6% of harmful errors across all four systems, including OpenEvidence, were errors of omission, meaning the AI left out critical information rather than stating something outright false. Doximity Ask scored best among the systems tested in this particular study, but cardiologist Eric Topol described even the top performers as carrying an illusion of readiness about their actual clinical capabilities, and argued that omission errors need to be driven as close to zero as possible given how easily missing information can be mistaken for a complete answer. The study’s more reassuring finding was that doctors using AI tools like OpenEvidence still gave better care overall than doctors working without them, provided they checked the cited sources rather than trusting the answer blindly.
Who OpenEvidence Is Best For
OpenEvidence fits doctors and students who need quick, cited answers for common questions. It is built for professionals, so the general public should rely on their own doctor rather than using it directly for personal medical decisions, since access itself requires verification as a licensed healthcare provider.
OpenEvidence vs Alternatives
| Tool | Why People Pick It |
|---|---|
| OpenEvidence | Free, citation-backed answers for verified clinicians |
| Doximity Ask | Scored best in a 2026 independent accuracy study |
| UpToDate | Long-established paid clinical reference |
Read also Abridge AI Review
A Million Consultations in a Single Day
On March 10, 2026, OpenEvidence recorded one million clinical consultations between verified physicians and its AI system within a single 24-hour period. CEO Daniel Nadler described it as marking the accelerating integration of medical AI into the fabric of healthcare. Independent studies cited by the company say OpenEvidence is now used by more American doctors than all other AI systems combined, and it has been named the best AI tool for medical information by the New England Journal of Medicine’s NEJM Journal Watch. Its investor base includes Google, Nvidia, and Sequoia Capital, and the company describes itself as the most valuable doctor technology company in the world, a claim consistent with its rapid climb to a $12 billion valuation.
Its content partnerships extend beyond Wiley to include NEJM, JAMA, the National Comprehensive Cancer Network, and the Cochrane Library, which is part of why the tool can answer with direct citations to some of the most respected names in medical publishing rather than generic web sources.
Frequently Asked Questions
What is OpenEvidence?
An AI tool that answers clinical questions using medical literature, used daily by more than 40% of US physicians according to its CEO.
Is OpenEvidence free?
Reviews say it is free for verified US healthcare professionals, funded by advertising rather than subscriptions.
Who is it for?
It is built for clinicians and students, with more than 757,000 verified physicians registered across over 10,000 hospitals and medical centers as of early 2026.
Does it give citations?
Yes, answers link to sources from peer reviewed journals and clinical guidelines.
Is it always accurate?
No. Reviewers report weaker results on complex cases, and a 2026 independent study found OpenEvidence shares the same tendency toward errors of omission as other leading medical AI tools, so users must verify every answer against the cited sources.
How much is OpenEvidence worth?
OpenEvidence was valued at $12 billion after a $250 million Series D round in January 2026, up from $1 billion less than a year earlier.
Who backs OpenEvidence financially?
Investors include Sequoia Capital, GV, Kleiner Perkins, Thrive Capital, DST Global, Google, and Nvidia, among others, across roughly $700 million in total funding through its Series D round.
What does the omission-error problem mean in practice?
It means the AI’s answer can look complete and well cited while quietly leaving out a detail that matters clinically, such as a contraindication or an alternative diagnosis to consider, rather than stating something factually wrong outright. That is harder to catch than an obvious error, which is why researchers like Eric Topol argue it deserves more attention than raw accuracy scores alone.
Final Verdict
OpenEvidence is a strong research helper for routine questions, with real adoption numbers and funding to back its growth. It supports professionals and does not replace their judgment, and independent research confirms it still needs the same source-checking discipline as any other clinical AI tool. Given how fast its valuation and daily usage have climbed, expect the free-for-clinicians model, feature set, and even the ad-based funding approach to keep evolving over the next year.
